Table 2.
Multivariate analysis for predicting bladder recurrence and cancer-specific free survival.
| Bladder recurrence | Cancer-specific free survival | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p-value | HR | 95% CI | p-value | |
| Age | 1.22 | 0.39-3.72 | 0.631 | 1.50 | 0.75-3.53 | 0.221 |
| Gender | 0.23 | 0.03-1.84 | 0.149 | 0.57 | 0.21-1.64 | 0.171 |
| Tumor location | 0.78 | 0.32-2.85 | 0.482 | 1.62 | 0.54-6.21 | 0.438 |
| Nuclear grade | 1.84 | 0.46-7.35 | 0.359 | 3.85 | 0.70-18.3 | 0.094 |
| LNI | 1.23 | 0.41-3.86 | 0.761 | 42.78 | 8.7-210.36 | 0.000 |
| LVI | 0.82 | 0.16-6.10 | 0.635 | 1.86 | 0.57-5.40 | 0.337 |
| Urine cytology | 1.78 | 0.43-7.26 | 0.325 | 1.33 | 0.81-2.36 | 0.110 |
| ACT | 14.862 | 3.20-68.99 | 0.001 | 1.94 | 0.55-5.77 | 0.210 |
HR : hazard ratio, CI : confidence interval, LNI : lymph node involvement, LVI : lymphovascular invasion, ACT : adjuvant chemotherapy.